Research progress on maintenance therapy following allogeneic hematopoietic stem cell transplantation for acute leukemia
10.12354/j.issn.1000-8179.2024.20240390
- VernacularTitle:急性白血病异基因造血干细胞移植后的维持治疗研究进展
- Author:
Yang CHUTING
1
;
Zheng YALING
;
Wu MING
;
Huang RUI
Author Information
1. 南方医科大学珠江医院血液内科(广州市 510282)
- Keywords:
acute leukemia(AL);
allogeneic hematopoietic stem cell transplantation(allo-HSCT);
maintenance therapy;
targeted ther-apy;
immunotherapy
- From:
Chinese Journal of Clinical Oncology
2024;51(12):635-639
- CountryChina
- Language:Chinese
-
Abstract:
Acute leukemia(AL)is a malignant clonal disease caused by hematopoietic stem cells.Depending on the cell type involved,AL is classified as acute lymphoblastic leukemia(ALL)or acute myeloid leukemia(AML).Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is an important and effective treatment for patients with AL to achieve long-term survival.However,recurrence after transplantation remains the primary cause of death.Pretransplantation status,transplantation conditioning,and prevention of post-transplantation relapse affects post-transplantation outcomes.This review focuses on post-transplantation maintenance therapy.Several studies on post-trans-plantation maintenance therapy are discussed,including research on post-transplantation maintenance therapy with epigenetic drugs,tar-geted drugs,and immunologic drugs.
